Enabling Global Participation in a Rare Disease Hybrid Study for Cerebral Adrenoleukodystrophy (CALD)

The Challenge

A global biopharmaceutical sponsor partnered with mdgroup to deliver a rare disease study focused on cerebral adrenoleukodystrophy (CALD). This rare manifestation of X-linked adrenoleukodystrophy (ALD) is a devastating genetic disorder that disrupts the breakdown of very-long-chain fatty acids (VLCFAs). The resulting buildup leads to progressive damage to the brain’s white matter and adrenal glands.

Adult CALD progresses rapidly, and without treatment, patients can reach a vegetative state or pass away within three to four years of symptom onset.

Because of the disease’s rarity, patients were enrolled from around the world to reach a sufficient sample size for research. The sponsor required a hybrid clinical trial model that included international travel coordination, reimbursement management, and home nursing visits.

The global scope of the study introduced several key challenges:

• Patients required ambulance transport and caregiver support to reach research sites.
• Participants traveled from diverse locations, including Russia, Albania, Malaysia, Australia, China, Europe, Latin America, and the United States.
• Some patients needed protocol visits conducted by qualified nurses and physicians in their home countries.
• The team had to navigate complex privacy laws, including GDPR, HIPAA, and regional regulations.

The Solution

mdgroup designed and delivered a comprehensive patient support program to remove logistical, financial, and regulatory barriers while maintaining the highest standards of cultural sensitivity and compliance.

The team began with a detailed needs assessment to identify patient demographics, logistical challenges, and cultural considerations across regions. From there, mdgroup coordinated all aspects of international and domestic travel, including flights, ground transportation, visa assistance, and accommodations tailored to each patient’s medical and personal needs. Accessible transport and caregiver arrangements were provided where required to ensure comfort and safety throughout the journey.

To reduce financial strain, the team established transparent and compliant reimbursement workflows aligned with local and regional regulations, creating an auditable system for managing travel and living expenses. For patients unable to travel, mdgroup partnered with trusted local nursing networks to schedule and monitor home-based clinical procedures, ensuring continuity of care without compromising protocol adherence.

Privacy and data protection were central to every step of delivery. A cross-border data protection framework was implemented, meeting GDPR, HIPAA, MR001, and other regional standards. Multilingual interpreters and translated study materials further supported clear communication and cultural understanding for patients and families across diverse geographies.

Through this integrated and carefully coordinated approach, mdgroup ensured every patient could participate in the study with confidence, comfort, and dignity, no matter where they lived.

The Outcome

Through this integrated, patient-first approach, mdgroup successfully supported global recruitment and retention while minimizing barriers to participation. The program led to increased patient enrollment and sustained engagement across multiple regions, while significantly reducing logistical and financial burdens for CALD participants and their caregivers. Throughout the study, mdgroup maintained full compliance with international privacy and data protection laws and delivered a culturally sensitive, compassionate experience that prioritized the comfort and confidence of every patient involved.

The Impact

For the sponsor, improved recruitment and retention rates demonstrated the effectiveness of removing logistical and financial barriers, while full compliance with global privacy laws reduced regulatory risk. Streamlined processes minimized administrative workload for study teams and strengthened the sponsor’s reputation among global sites and patients.

Healthcare professionals and site staff also benefited from higher protocol compliance, fewer missed appointments, and clearer communication through multilingual and culturally sensitive support. With travel and reimbursement handled externally, site teams were able to focus fully on clinical care.

For patients and their families, comprehensive travel and financial assistance eliminated obstacles to participation. Home nursing visits ensured continuity of care, while transparent consent processes and secure data handling reinforced confidence in the study.

The Difference

By combining global reach, cultural intelligence, and technology-enabled compliance, mdgroup delivered a hybrid model that made participation in this rare disease study both possible and empowering for patients worldwide.

This project demonstrates mdgroup’s ongoing commitment to delivering patient driven clinical solutions that make the clinical experience more human, no matter how complex the challenge.